CD70 and nasopharyngeal carcinoma: Finally, this lipid-driven immunosuppressive mechanism induced by CD70-CD27 signaling opens CD70-targeted precision therapy as additional avenue for NPC patients, and is potentially feasible and effective in patients with melanoma, depending on their specific TME landscapes.